11 research outputs found

    Manifestaciones hematológicas poco frecuentes en el lupus eritematoso sistémico: púrpura trombótica trombocitopénica, aplasia pura de células rojas y síndrome hemofagocítico. Estudio descriptivo en una serie de pacientes del registro español de pacientes con lupus eritematoso sistémico (RELESSER)

    Get PDF
    Programa Oficial de Doutoramento en Ciencias da Saúde. 5007V01.[Resumen] Introducción: las manifestaciones hematológicas del lupus eritematoso sistémico (LES) son frecuentes. Sin embargo, la púrpura trombótica trombocitopénica (PTT), la aplasia pura de células rojas (APCR) y el síndrome hemofagocítico (SH) tienen una baja prevalencia. Objetivo: describir los pacientes incluidos en el registro nacional de LES de la Sociedad Española de Reumatología (RELESSER) con estas tres manifestaciones y analizarlos comparativamente con los casos descritos en la literatura. Métodos: estudio clínico-epidemiológico, retrospectivo, observacional, multicéntrico con base hospitalaria de los pacientes de RELESSER diagnosticados de PTT, APCR o SH y de su evolución a medio y largo plazo. Revisión bibliográfica de los casos publicados hasta junio de 2016. Resultados: de los 3.658 pacientes incluidos en RELESSER se detectaron 19 casos de PTT, 5 de APCR y 7 de SH (prevalencia <0.5%). La mayoría se presentaron tras el diagnóstico de LES. Los principales desencadenantes fueron infecciones y actividad grave del lupus eritematoso sistémico. La mayoría de los pacientes requirieron ingreso hospitalario, así como tratamiento con glucocorticoides e inmunosupresores. La PTT y el SH presentaron un 10,5% y 28,6% de recidivas y una mortalidad del 10,5% y 14,2%, respectivamente. Conclusiones: la prevalencia de la PTT, la APCR y el SH en el LES es baja (<0,5%). Su diagnóstico suele realizarse tras el diagnóstico de LES. La PTT y el SH son particularmente graves, ocasionando ingresos prolongados de los pacientes y múltiples terapias. Puesto que la tasa de mortalidad de la PTT y el SH es significativa, debe realizarse un diagnóstico y tratamiento precoz de las complicaciones con el fin de reducir dicha mortalidad.[Resumo] Introdución: as manifestacións hematolóxicas do lupus eritematoso sistémico (LES) son frecuentes. Sen embargo a púrpura trombótica trombocitopénica (PTT), a aplasia pura de células vermellas (APCV) e a síndrome hemofagocítica (SH) teñen una baixa prevalencia. Obxectivo: describir os doentes incluidos no Rexistro nacional de lupus da Sociedade Española de Reumatoloxía (RELESSER), con estas tres manifestacións e analizarlos comparativamente cos casos descritos na literatura. Métodos: estudo clínico-epidemiolóxico, retrospectivo, observacional, multicéntrico con base hospitalaria dos doentes de RELESSER diagnosticados de PTT, APCV o SH e da sua evolución a medio e longo prazo. Revisión bibliográfica dos casos publicados hasta xuño de 2016. Resultados: dos 3.658 pacientes incluidos en RELESSER se detectaron 19 casos de PTT, 5 casos de APCV e 7 casos de SH (prevalencia <0,5%). A maioría presentáronse despois do diagnóstico de lupus eritematoso sistémico. Os principais desencadenantes foron as infeccións e a actividade grave do lupus eritematoso sistémico. A mayoría dos pacientes precisaron ingreso hospitalario, así como tratamento con glucocorticoides e inmunosupresores. A púrpura trombótica trombocitopénica e a síndrome hemofagocítica presentaron un 10,5% y 28,6% de recidivas e unha mortalidad del 10,5% y 14,2%, respetivamente. Conclusións: a prevalencia da PTT, a APCV e a SH no LES e baixa (<0.5%). O seu diagnóstico adoita ser despois do diagnóstico do LES. A PTT e a SH son particularmente graves, ocasionando ingresos prolongados dos doentes e múltples terapias. Posto que a taxa de mortalidade na PTT e na SH é significativa, debe realizarse un diagnóstico e tratamento precoz das complicacións con fin de reducir dita mortalidad.[Abstract] Introduction: Hematologic manifestations are common in systemic lupus erythematosus (SLE). However, thrombotic thrombocytopenic purpura (TTP), pure red cell aplasia (PRCA) and hemophagocytic syndrome (HS) are unfrequent. Objective: to describe the patients with systemic lupus erythematosus included in the National Register of lupus of the Spanish Society of Rheumatology (RELESSER) with these manifestations, and to analyze such patients comparatively with the cases described in the literature. Methods: a clinical, epidemiological, retrospective, observational, multicentric study, hospital based of RELESSER patients diagnosed with TTP, PRCA and HS. Study of medium and long term outcomes. Review of the literatura until June 2016. Results: from the 3,658 patients included in RELESSER, 19 cases of TTP, 5 cases of PRCA and 7 cases of HS (prevalence <0.5%) were detected. The majority of the cases occurred after the diagnosis of SLE. Infections and severe activity of systemic lupus erythematosus were the major triggers. Most of the patients required hospitalization and treatment with corticosteroids and immunosuppressive drugs. The TTP and HS presented 10.5% and 28.6% of relapses, and a mortality rate of 10.5% and 14.2% respectively. Conclusions: The prevalence of TTP, PRCA and HS in SLE is low (<0.5%). The diagnosis is usually made after SLE diagnosis. TTP and HS are specially serious, causing long hospitalizations and needing multiple therapies. As the mortality rate in TTP and HS is significative, an early diagnose and treatment is important to decrease the mortality

    Correction : Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885

    Get PDF
    The authors wish to make the following corrections to this paper [...]

    Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain : Large-Scale Epidemiological Study

    Get PDF
    (1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

    No full text
    corecore